Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy
新型TNFR2拮抗单克隆抗体用于CTCL治疗的临床前毒理学和药理学评价
基本信息
- 批准号:10772580
- 负责人:
- 金额:$ 122.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody TherapyAutoimmunityBenchmarkingBindingBostonCancer PatientCancerousCapitalCellsClinicalClinical TrialsColon CarcinomaCutaneous T-cell lymphomaCyclic GMPDataDevelopmentDoseDrug KineticsEffector CellEvaluationFormulationFrequenciesFundingFutureGrowthGuidelinesHealthHealth Care CostsHealth ExpendituresHumanImmuneImmune checkpoint inhibitorImmune systemImmunooncologyImmunotherapyIn VitroInfiltrationInternationalInvestigational DrugsInvestigational New Drug ApplicationMacaca fascicularisMalignant NeoplasmsMalignant neoplasm of ovaryMarketingMediatingMolecular TargetMonoclonal AntibodiesMusNew Drug ApprovalsOncogenesOncogenicPatientsPersonsPharmacologic SubstancePharmacology and ToxicologyPhaseProcessProductionProductivityReceptors, Tumor Necrosis Factor, Type IIRegulatory AffairsRegulatory T-LymphocyteReportingResistanceSafetySamplingSecureSignal TransductionSmall Business Innovation Research GrantSocietiesSurfaceTNFRSF1A geneTechnologyTestingTherapeuticTimeTissuesToxic effectToxicologyValidationantagonistanti-tumor immune responseantitumor effectcGMP productioncancer cellcancer infiltrating T cellscancer therapydesigndimerin vitro activityin vivoinnovationinterestlarge scale productionmanufacturing runnovel strategiesnovel therapeutic interventionnovel therapeuticsoverexpressionpharmacologicpre-clinicalpreventprogrammed cell death protein 1programsreceptorresearch clinical testingselective expressiontargeted cancer therapytargeted treatmenttherapeutic targettherapy outcometooltumortumor microenvironmenttumor necrosis factor receptor bindingvalidation studies
项目摘要
PROJECT SUMMARY
Cancer has killed over 600,000 people in US in 2020. The cost for healthcare and society is unbearable: because
of cancer, $180B healthcare expenditure and $134B lost productivity are recorded every year. This is happening
despite recent advancements in therapy and the emergence of an ever expanding array of new therapeutics for
the over 1.8M new cancer patients every year. Indeed, because of the multitude and redundancy of mechanisms
contributing to cancer growth, therapies are often ineffective. Several components should be targeted at the
same time in order to maximize therapy outcome. However, this is particular hard to attain because of 1) the
striking variability among cancers and the limited number of cancer specific targets 2) the ability of cancer cells
to orchestrate a microenvironment of healthy tissue and cells around them, that promote cancer growth and
therapy resistance. Boston Immune Technologies and Therapeutics (BITT) is developing BITT-1492, able to
target both cancer cells and their microenvironment. BITT-1492 is an antagonist antibody against TNFR2 – a
receptor highly expressed in cancer tissue and immune suppressive cells in the microenvironment, where it
mediates pro-survival signaling. Thanks to BITT’s proprietary antibody design platform, BITT-1492 is the first
and only antibody able to dominantly shut down TNFR2 signaling. Due to selective expression and key role of
TNFR2 for a variety of cancers and tumor microenvironment cells, BITT-1492 will find application in the therapy
of several cancers, starting with Cutaneous T cell Lymphoma (CTCL), where TNFR2 is known to act as an
extremely potent oncogene. BITT has already completed extensive pre-clinical validation for BITT-1492,
demonstrating potent activity in CTCL, colon and ovarian cancers. In the proposed Fast-Track project, BITT will
complete a pre-clinical toxicology and pharmacology assessment of BITT-1492 to obtain relevant data for an
Investigational New Drug (IND) application. This will be accomplished by performing, in line with ICH guidelines,
an exploratory small-scale toxicology study to be carried out in Phase I, that will demonstrate the safety of use
of BITT-1492 for a wider IND-enabling toxicology and pharmacokinetic studies in Phase II. As part of the PhaseII
BITT will also test the suitability of BITT-1492 production process for cGMP standard compliance. At the end of
the SBIR project, BITT will be ready to advance BITT-1492 to clinical testing for which a combination of Venture
Capital seed funds and SBIR PhaseIIb are expected to be leveraged. The successful completion of this project
and initial clinical testing evidence will help to secure the already expressed interest of pharmaceutical
companies with whom BITT will engage to complete late-stage clinical testing and launch BITT-1492 into
international markets.
项目总结
2020年,美国已有60多万人死于癌症。医疗保健和社会的成本是无法承受的:因为
在癌症方面,每年记录的医疗支出为1800亿美元,生产力损失为1340亿美元。这件事正在发生
尽管最近在治疗方面取得了进展,出现了一系列不断扩大的新疗法,
每年新增癌症患者超过180万人。事实上,由于机制的多重性和冗余性
导致癌症生长的治疗方法往往是无效的。有几个组件应该针对
同时为了最大限度地提高治疗效果。然而,这一点尤其难以实现,因为1)
癌症之间的显著变异性和癌症特异性靶点的数量有限2)癌细胞的能力
协调健康组织及其周围细胞的微环境,促进癌症生长和
治疗抵抗。波士顿免疫技术和治疗公司(BITT)正在开发BITT-1492,能够
针对癌细胞及其微环境。BITT-1492是一种针对TNFR2-a的拮抗性抗体
受体在肿瘤组织和免疫抑制细胞的微环境中高表达,在那里它
调节支持生存的信号。由于Bitt的专有抗体设计平台,Bitt-1492是第一个
并且只有抗体能够显性地关闭TNFR2信号转导。由于选择性表达和关键作用
针对多种肿瘤和肿瘤微环境细胞,BITT-1492将在治疗中得到应用
在几种癌症中,从皮肤T细胞淋巴瘤(CTCL)开始,TNFR2被认为是一种
极强的致癌基因。BITT已经完成了对BITT-1492的广泛临床前验证,
在CTCL、结肠癌和卵巢癌中表现出很强的活性。在拟议的快速通道项目中,Bitt将
完成BITT-1492的临床前毒理学和药理学评估,以获得
研究用新药(IND)申请。这将通过按照非物质文化遗产指导方针,
将在第一阶段进行的探索性小规模毒理学研究,将证明使用的安全性
BITT-1492在第二阶段进行更广泛的IND毒理学和药代动力学研究。作为第二阶段的一部分
BITT还将测试BITT-1492生产工艺是否符合cGMP标准。在…的末尾
SBIR项目,BITT将准备将BITT-1492推进到临床测试,针对该测试,Venture
资本种子基金和SBIR PhaseIIb预计将得到杠杆利用。这项工程的圆满完成
初步的临床测试证据将有助于确保已经表达了对制药的兴趣
BITT将与其合作完成后期临床测试并将BITT-1492推出到
国际市场。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kenneth Olivier其他文献
Kenneth Olivier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kenneth Olivier', 18)}}的其他基金
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
推进 BITT-101 成为一种新型 CD40 拮抗剂,用于治疗干燥综合征。
- 批准号:
10760568 - 财政年份:2023
- 资助金额:
$ 122.17万 - 项目类别:
Preclinical toxicology and pharmacology evaluation of a newTNFR2 antagonistic monoclonal antibody for CTCL therapy
新型TNFR2拮抗单克隆抗体用于CTCL治疗的临床前毒理学和药理学评价
- 批准号:
10323802 - 财政年份:2021
- 资助金额:
$ 122.17万 - 项目类别:
Pulmonary clinical medicine: PFT lab, bronchoscopy, consultation services, and education
肺部临床医学:PFT实验室、支气管镜检查、咨询服务和教育
- 批准号:
9788012 - 财政年份:
- 资助金额:
$ 122.17万 - 项目类别:
Pulmonary clinical medicine: PFT lab, bronchoscopy, consultation services, and education
肺部临床医学:PFT实验室、支气管镜检查、咨询服务和教育
- 批准号:
9157603 - 财政年份:
- 资助金额:
$ 122.17万 - 项目类别:
Pulmonary clinical medicine: PFT lab, bronchoscopy, consultation services, and education
肺部临床医学:PFT实验室、支气管镜检查、咨询服务和教育
- 批准号:
10253954 - 财政年份:
- 资助金额:
$ 122.17万 - 项目类别:
Pulmonary clinical medicine: PFT lab, bronchoscopy, consultation services, and education
肺部临床医学:PFT实验室、支气管镜检查、咨询服务和教育
- 批准号:
10008883 - 财政年份:
- 资助金额:
$ 122.17万 - 项目类别:
Inflammatory and immune dysregulation associated lung disease
炎症和免疫失调相关的肺部疾病
- 批准号:
9572321 - 财政年份:
- 资助金额:
$ 122.17万 - 项目类别:
Pulmonary clinical medicine: PFT lab, bronchoscopy, consultation services, and education
肺部临床医学:PFT实验室、支气管镜检查、咨询服务和教育
- 批准号:
9357331 - 财政年份:
- 资助金额:
$ 122.17万 - 项目类别:
相似海外基金
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
- 批准号:
MR/Y008847/1 - 财政年份:2024
- 资助金额:
$ 122.17万 - 项目类别:
Research Grant
Development of CD81 Antibody Therapy for Osteosarcoma - Focused on Exosomes -
骨肉瘤 CD81 抗体疗法的开发 - 专注于外泌体 -
- 批准号:
23K08593 - 财政年份:2023
- 资助金额:
$ 122.17万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus
IN-002 的 GMP 生产和 IND 备案,这是一种针对呼吸道合胞病毒的有效吸入粘液捕获抗体疗法
- 批准号:
10761398 - 财政年份:2023
- 资助金额:
$ 122.17万 - 项目类别:
SBIR Phase I: Antibody Therapy that Targets Neoantigens in Acute Myeloid Leukemia via the Antibody Dependent Cell-mediated Cytotoxicity Mechanism of Natural Killer Cells
SBIR 第一期:通过抗体依赖性细胞介导的自然杀伤细胞的细胞毒性机制,针对急性髓性白血病新抗原的抗体疗法
- 批准号:
2246487 - 财政年份:2023
- 资助金额:
$ 122.17万 - 项目类别:
Standard Grant
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
- 批准号:
10511223 - 财政年份:2022
- 资助金额:
$ 122.17万 - 项目类别:
Precise Modulation of Immunometabolism to Boost Antibody Therapy in Oral Cancer
精确调节免疫代谢以促进口腔癌的抗体治疗
- 批准号:
10643886 - 财政年份:2022
- 资助金额:
$ 122.17万 - 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
- 批准号:
10511323 - 财政年份:2022
- 资助金额:
$ 122.17万 - 项目类别:
Re-designing anti-CD20 monoclonal antibody therapy using novel insights into limitations of innate immune cytotoxicity
利用对先天免疫细胞毒性局限性的新见解重新设计抗 CD20 单克隆抗体疗法
- 批准号:
10657706 - 财政年份:2022
- 资助金额:
$ 122.17万 - 项目类别:
Hacking Co-Stimulatory Receptors with Targeted Checkpoint Antibody Therapy
用靶向检查点抗体疗法攻击共刺激受体
- 批准号:
574961-2022 - 财政年份:2022
- 资助金额:
$ 122.17万 - 项目类别:
University Undergraduate Student Research Awards
Imaging the multifaceted response to a bispecific antibody therapy
双特异性抗体疗法的多方面反应成像
- 批准号:
10451574 - 财政年份:2021
- 资助金额:
$ 122.17万 - 项目类别: